FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311194854> ?p ?o ?g. }

• W4311194854 endingPage "A22" @default.
• W4311194854 startingPage "A22" @default.
• W4311194854 abstract "Abstract Triple-Negative Breast Cancer (TNBC) patients that do not respond to neoadjuvant chemotherapy account for 60-70% of all cases and are orphans of therapeutic alternatives after chemotherapy failure. Despite the great progress that has been made in the application of immune-based strategies, clinical opportunities for TNBC patients are still lacking. We aimed to investigate the molecular mechanisms leading to the activation of the TNBC immunological microenvironment, thus providing novel clues for the design and development of immune-based therapeutic approaches and adoptive immune cell therapies for TNBC patients. We analyzed consecutive TNBC cases treated at AUSL-IRCCS Hospital of Reggio Emilia from 2011 to 2017. 24 Tru-Cut biopsies were selected, comparing 12 patients with pathological complete response (pCR) after neoadjuvant treatment and 12 patients with cancer progression. Then, we performed a morphology-guided transcriptome profiling of the immune infiltrate using our GeoMx-Digital spatial profiler (DSP) to investigate which immune populations were associated with a more favorable outcome. The immune infiltrate of patients showing pCR was significantly enriched for activated Natural Killer (NK) cells, compared to patients with disease progression. Intriguingly, both T-helper CD4- and CD8-T lymphocytes did not reach statistical significance, suggesting a secondary involvement in predicting neoadjuvant efficacy in TNBC patients. We confirmed that NK cells can significantly impair TNBC cell proliferation and viability in vitro and improved the efficacy of chemotherapeutic drugs (paclitaxel, docetaxel). To increase our knowledge of the molecular mechanisms governing NK effector functions toward TNBC, we decided to investigate the specific transcriptional landscape that triggers NK cell activation. We profiled the transcriptome of activated NK cells by RNA-sequencing, identifying several de-regulated pathways involved in NK innate anti-tumor response, including the down-regulation of Immune checkpoint (IC) molecules (CTLA4, CEACAM3, PD1, KIR2DL4, KIR3DX1, KIR3DL3, TIGIT, TIM3, LAG3, etc) and the up-regulation of vesicle-trafficking and autophagy-related proteins (STX5, STX7, BNIP3L, SNAP29, GABARAPL1, RAB4B, etc). To predict upstream transcription regulators, promoters of de-regulated genes were in silico scanned for common binding motifs with the FIMO algorithm, thus identifying a list of candidate Transcription Factors (TFs). Among top-scoring TFs, we identified PAX5 which has been already involved in NK differentiation and cytotoxicity. Other top-scoring TFs are currently under investigation as potential NK Master Regulators of their effector functions, including SMAD3, VEZF1, and MAZ. Overall, our results point out the relevance of NK cells in predicting neoadjuvant treatment response in TNBC patients. Moreover, the modulation of the NK transcriptional program may be a novel tool to potentiate their anti-tumor potential, thus proving novel clues to optimize their application in adoptive cell therapies and in the treatment of TNBC patients. Citation Format: Francesca Reggiani, Benedetta Donati, Moira Ragazzi, Veronica Manicardi, Federica Torricelli, Elisabetta Sauta, Elisa Gasparini, Simonetta Piana, Valentina Sancisi, Alessia Ciarrocchi. Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies? [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A22." @default.
• W4311194854 created "2022-12-24" @default.
• W4311194854 creator A5006240105 @default.
• W4311194854 creator A5014045886 @default.
• W4311194854 creator A5020969433 @default.
• W4311194854 creator A5032014419 @default.
• W4311194854 creator A5042559824 @default.
• W4311194854 creator A5060916338 @default.
• W4311194854 creator A5079069793 @default.
• W4311194854 creator A5083501037 @default.
• W4311194854 creator A5089969449 @default.
• W4311194854 creator A5012016969 @default.
• W4311194854 date "2022-12-01" @default.
• W4311194854 modified "2023-09-27" @default.
• W4311194854 title "Abstract A22: Deciphering natural killer transcriptional activation in triple-negative breast cancer: A novel opportunity for adoptive cell therapies?" @default.
• W4311194854 doi "https://doi.org/10.1158/2326-6074.tumimm22-a22" @default.
• W4311194854 hasPublicationYear "2022" @default.
• W4311194854 type Work @default.
• W4311194854 citedByCount "0" @default.
• W4311194854 crossrefType "journal-article" @default.
• W4311194854 hasAuthorship W4311194854A5006240105 @default.
• W4311194854 hasAuthorship W4311194854A5012016969 @default.
• W4311194854 hasAuthorship W4311194854A5014045886 @default.
• W4311194854 hasAuthorship W4311194854A5020969433 @default.
• W4311194854 hasAuthorship W4311194854A5032014419 @default.
• W4311194854 hasAuthorship W4311194854A5042559824 @default.
• W4311194854 hasAuthorship W4311194854A5060916338 @default.
• W4311194854 hasAuthorship W4311194854A5079069793 @default.
• W4311194854 hasAuthorship W4311194854A5083501037 @default.
• W4311194854 hasAuthorship W4311194854A5089969449 @default.
• W4311194854 hasConcept C121608353 @default.
• W4311194854 hasConcept C126322002 @default.
• W4311194854 hasConcept C143998085 @default.
• W4311194854 hasConcept C167672396 @default.
• W4311194854 hasConcept C203014093 @default.
• W4311194854 hasConcept C2776090121 @default.
• W4311194854 hasConcept C2776107976 @default.
• W4311194854 hasConcept C2777701055 @default.
• W4311194854 hasConcept C2778326572 @default.
• W4311194854 hasConcept C2780110267 @default.
• W4311194854 hasConcept C502942594 @default.
• W4311194854 hasConcept C530470458 @default.
• W4311194854 hasConcept C71924100 @default.
• W4311194854 hasConcept C8891405 @default.
• W4311194854 hasConceptScore W4311194854C121608353 @default.
• W4311194854 hasConceptScore W4311194854C126322002 @default.
• W4311194854 hasConceptScore W4311194854C143998085 @default.
• W4311194854 hasConceptScore W4311194854C167672396 @default.
• W4311194854 hasConceptScore W4311194854C203014093 @default.
• W4311194854 hasConceptScore W4311194854C2776090121 @default.
• W4311194854 hasConceptScore W4311194854C2776107976 @default.
• W4311194854 hasConceptScore W4311194854C2777701055 @default.
• W4311194854 hasConceptScore W4311194854C2778326572 @default.
• W4311194854 hasConceptScore W4311194854C2780110267 @default.
• W4311194854 hasConceptScore W4311194854C502942594 @default.
• W4311194854 hasConceptScore W4311194854C530470458 @default.
• W4311194854 hasConceptScore W4311194854C71924100 @default.
• W4311194854 hasConceptScore W4311194854C8891405 @default.
• W4311194854 hasIssue "12_Supplement" @default.
• W4311194854 hasLocation W43111948541 @default.
• W4311194854 hasOpenAccess W4311194854 @default.
• W4311194854 hasPrimaryLocation W43111948541 @default.
• W4311194854 hasRelatedWork W2891560139 @default.
• W4311194854 hasRelatedWork W2904909612 @default.
• W4311194854 hasRelatedWork W2908970744 @default.
• W4311194854 hasRelatedWork W2938706471 @default.
• W4311194854 hasRelatedWork W3039388108 @default.
• W4311194854 hasRelatedWork W3120170523 @default.
• W4311194854 hasRelatedWork W3154849375 @default.
• W4311194854 hasRelatedWork W3165724578 @default.
• W4311194854 hasRelatedWork W4291378227 @default.
• W4311194854 hasRelatedWork W4309781227 @default.
• W4311194854 hasVolume "10" @default.
• W4311194854 isParatext "false" @default.
• W4311194854 isRetracted "false" @default.
• W4311194854 workType "article" @default.